Literature DB >> 8527010

How important is therapeutic drug monitoring in the prediction and avoidance of adverse reactions?

C A Gentry1, K A Rodvold.   

Abstract

Mesh:

Year:  1995        PMID: 8527010     DOI: 10.2165/00002018-199512060-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  42 in total

1.  Hospital pharmacy compliance with JCAHO standards and ASHP guidelines for reporting adverse drug reactions.

Authors:  L S Tyler; N A Nickman
Journal:  Am J Hosp Pharm       Date:  1992-04

2.  Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.

Authors:  M J Ratain; R Mick; R L Schilsky; N J Vogelzang; F Berezin
Journal:  J Clin Oncol       Date:  1991-08       Impact factor: 44.544

3.  Plasma digoxin concentrations and digoxin toxicity in hospital patients.

Authors:  D C Evered; C Chapman
Journal:  Br Heart J       Date:  1971-07

4.  The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia.

Authors:  R D Moore; C R Smith; P S Lietman
Journal:  J Infect Dis       Date:  1984-03       Impact factor: 5.226

5.  Does accepting pharmacokinetic recommendations impact hospitalization? A cost-benefit analysis.

Authors:  C J Destache; S K Meyer; K M Rowley
Journal:  Ther Drug Monit       Date:  1990-09       Impact factor: 3.681

6.  Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia.

Authors:  R D Moore; C R Smith; P S Lietman
Journal:  Am J Med       Date:  1984-10       Impact factor: 4.965

7.  Iatrogenic illness on a general medical service at a university hospital.

Authors:  K Steel; P M Gertman; C Crescenzi; J Anderson
Journal:  N Engl J Med       Date:  1981-03-12       Impact factor: 91.245

8.  Positive impact of a therapeutic drug-monitoring program on total aminoglycoside dose and cost of hospitalization.

Authors:  K D Crist; M C Nahata; J Ety
Journal:  Ther Drug Monit       Date:  1987-09       Impact factor: 3.681

9.  Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole.

Authors:  D L Trump; M J Egorin; A Forrest; J K Willson; S Remick; K D Tutsch
Journal:  J Clin Oncol       Date:  1991-11       Impact factor: 44.544

10.  Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer.

Authors:  S C Piscitelli; K A Rodvold; D A Rushing; D A Tewksbury
Journal:  Clin Pharmacol Ther       Date:  1993-05       Impact factor: 6.875

View more
  1 in total

Review 1.  Therapeutic drug monitoring: do the improved outcomes justify the costs?

Authors:  G E Schumacher; J T Barr
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.